Recent ICCM News
- IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer • PR Newswire (US) • 04/15/2024 12:35:00 PM
- IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance • PR Newswire (US) • 04/03/2024 12:30:00 PM
- U.S. Futures Dip in Pre-Market, May WTI and June Brent Crude Prices Edge Higher • IH Market News • 04/03/2024 11:11:59 AM
- IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes • PR Newswire (US) • 04/02/2024 12:30:00 PM
- IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024 • PR Newswire (US) • 03/27/2024 12:30:00 PM
- IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy • PR Newswire (US) • 03/19/2024 12:30:00 PM
- IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes • PR Newswire (US) • 03/12/2024 12:30:00 PM
- IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference • PR Newswire (US) • 03/07/2024 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/04/2024 01:35:29 PM
- IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024 • PR Newswire (US) • 03/04/2024 01:30:00 PM
- Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop • PR Newswire (US) • 02/27/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 01:15:29 PM
- Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer • PR Newswire (US) • 02/26/2024 01:00:00 PM
- IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan • PR Newswire (US) • 02/15/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 01:15:02 PM
- U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer • PR Newswire (US) • 01/30/2024 01:00:00 PM
- IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class • PR Newswire (US) • 01/29/2024 01:00:00 PM
- IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation • PR Newswire (US) • 01/16/2024 01:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/12/2024 09:39:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/12/2024 09:18:50 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/12/2024 09:10:20 PM
- IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule • GlobeNewswire Inc. • 01/12/2024 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/10/2024 01:15:26 PM
- IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results • PR Newswire (US) • 01/10/2024 01:00:00 PM
- New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response • PR Newswire (US) • 01/03/2024 01:00:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM